Fortress Biotech (FBIO) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on June 17, 2026, with shareholders voting on the election of seven directors and the ratification of KPMG LLP as the independent auditor for 2026.
Shareholders of record as of April 21, 2026, are entitled to vote, with one vote per share; voting can be done online, by phone, mail, or during the meeting.
Proxy materials are distributed electronically, with paper copies available upon request; voting instructions and technical support are provided for virtual participation.
Voting matters and shareholder proposals
Shareholders will vote on electing seven directors for a one-year term and ratifying KPMG LLP as the independent registered public accounting firm for 2026.
The Board recommends voting FOR all director nominees and FOR the ratification of KPMG LLP.
Shareholders may submit proposals for the 2027 Annual Meeting by December 29, 2026, and director nominations must comply with advance notice requirements.
Board of directors and corporate governance
The Board consists of seven members, with a mix of executive and independent directors; independence is reviewed annually per Nasdaq standards.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and independent membership.
Directors are evaluated on experience, integrity, and commitment; stockholders can recommend candidates for nomination.
Directors are expected to attend all meetings, and a process exists for shareholder communications with the Board.
Latest events from Fortress Biotech
- Q2 2026 revenue up 14% to $18.7M, with a $158.9M PRV gain and strong cash reserves.FBIO
Q2 2026 - Triplex delivers robust efficacy and safety in CMV prevention for transplants, targeting $1B+ peak sales.FBIO
Corporate presentation - Proprietary bioreactor boosts MSC potency, enabling lower dosing and major cost savings.FBIO
Corporate presentation - Directors and auditors for 2026 were approved by shareholders, concluding the meeting.FBIO
AGM 2026 - Three FDA approvals, strong revenue, and a robust late-stage pipeline drive near-term growth.FBIO
Corporate presentation - Scalable, royalty-driven model and recent monetizations fuel growth and strengthen financial position.FBIO
A.G.P.'s Annual Virtual Healthcare Conference - Q1 2026 net income jumped to $108.4M on a $205M PRV sale and 21–22% revenue growth.FBIO
Q1 2026 - Virtual vote set for June 2026 on director elections and auditor ratification.FBIO
Proxy filing - Two FDA approvals and a major acquisition highlight Fortress Biotech's transformative 2024.FBIO
Q4 2024